When doctors treat epithelioid mesothelioma, they use a mix of treatments. Treatment guidelines often include chemotherapy and surgery. But, a new study looked at whether patients were getting these recommended treatments and how it affected how long they lived.
The Role of Guidelines in Prolonging Life
A recent study checked data from an extensive database of mesothelioma patients between 2004 and 2016. They wanted to see if doctors followed the guidelines and if that affected how well patients did.
They found something surprising. Only about 19% of 3,534 patients got the treatments that doctors usually recommend. Also, certain patients were more likely to get the recommended treatment. These were younger patients or those with insurance. Also, people living in wealthier areas and those treated at special research centers.
But here’s the important part. Mesothelioma patients who got the recommended treatments tended to live longer. Those who got the right treatments lived for around 24.7 months, while those who didn’t got around 13.7 months. That’s almost twice as long.
How Guideline-Backed Therapies Impact Mesothelioma Outcomes
Despite the clear benefits of these treatments, most patients weren’t getting them. This means that patients might not be getting the best possible care for their cancer.
This study shows that sticking to the treatment guidelines can help mesothelioma patients live longer. It also shows that many patients aren’t getting the recommended treatments. This might be making it harder for them to get better.
Ultimately, doctors and patients need to know about these guidelines. And they need to try their best to follow them. Making sure more patients get the recommended treatments could make a difference in how well they do against this challenging type of cancer.
Liou, Douglas Z., Yoyo Wang, Prasha Bhandari, Joseph B. Shrager, Natalie S. Lui, Leah M. Backhus, and Mark F. Berry. “Impact of Guideline Therapy on Survival of Patients with Stage I–III Epithelioid Mesothelioma.” Journal of Thoracic Disease 15, no. 12 (2023). https://cdn.amegroups.cn/journals/pbpc/files/journals/2/articles/81618/public/81618-PB1-4737-R1.pdf.